Neratinib

Chemical formula: C₃₀H₂₉ClN₆O₃ Molecular mass: 557.05 g/mol PubChem compound: 9915743

Therapeutic indications

Neratinib is indicated for:

HR-positive, HER2-positive breast cancer

Population group: only adults (18 years old or older)

Neratinib is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

240 mg once daily, continuously for one year

Advanced or metastatic HER2-positive breast cancer

Population group: only adults (18 years old or older)

Neratinib in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

240 mg once daily until disease progression or unacceptable toxicities

Contraindications

Neratinib is contraindicated in the following cases:

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Strong CYP3A4/P-gp inducers

Strong potency CYP3A4 inducers and additionally P-glycoprotein inducers

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.